NEURISE

Calcium Channel Blocker

Nimodipine is used to treat symptoms resulting from a ruptured blood vessel in the brain (subarachnoid hemorrhage). It works by increasing the blood flow to injured brain tissue. This medicine is available only with your doctor’s prescription.

General Info

Category:	Neuroprotective / Antihypertensive
PRODUCT INFORMATION :	Generic Name: NIMODIPINE Composition: Each film coated tablet contains: Nimodipine 30 mg tablets Therapeutic Category: Neuroprotective / Antihypertensive Pharmacological Category: Dihydropyridine Calcium Channel Blocker (CCB) Pregnancy Category: C (Use only if benefits outweigh risks) Lactation: Use with caution Pack Size: 10 x 10s
INDICATIONS :	Prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage (SAH) Improves neurological outcome after aneurysmal rupture Off-label uses: cognitive disorders, vascular dementia (not routinely recommended)
PHARMACOKINETICS:	Absorption: Rapidly absorbed after oral administration Bioavailability: ~13% (due to first-pass hepatic metabolism) Protein Binding: >95% Metabolism:Extensive hepatic metabolism (CYP3A4) Half-life: ~8–9 hours Elimination: Mainly in feces; minor renal excretion
DOSAGE INFORMATION:	Subarachnoid Hemorrhage (SAH) Prophylaxis: 60 mg orally every 4 hours for 21 days, starting within 96 hours of SAH Elderly or hypotensive patients: Lower initial dose may be considered (30 mg every 4 hours) NOTE: Administer on empty stomach, avoid grapefruit juice (CYP3A4 interaction)
SIDE EFFECTS:	Hypotension Dizziness or lightheadedness Headache Nausea Bradycardia (rare) Flushing Elevated liver enzymes (rare)
PRECAUTIONS:	Use caution in patients with liver impairment (reduce dose) Monitor blood pressure regularly Avoid in patients at risk of cerebral ischemia from excessive BP reduction Not recommended for intravenous use (only oral/nasogastric)
CONTRAINDICATIONS:	Severe hypotension (systolic BP < 90 mmHg) Known hypersensitivity to nimodipine or other dihydropyridine CCBs Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, ritonavir) Intravenous use of oral solution (can cause cardiovascular collapse)